Agenus Secures Expanded Cancer Therapy Access in France After $141M Deal

Agenus has expanded reimbursement access in France for its BOT/BAL combination therapy. The treatment is now available for patients with platinum-resistant ovarian cancer and advanced soft tissue sarcomas. This follows a major partnership deal with Zydus Lifesciences announced earlier this year.

In January 2026, Agenus finalised a strategic agreement with Zydus Lifesciences worth up to $141 million. The deal included a $75 million upfront payment, along with an additional $16 million from a share placement. After the announcement, the company's valuation reached $159.16 million.

The new funding will support Agenus's plans to launch the Phase 3 BATTMAN trial in 2026. This pivotal study will further test the BOT/BAL combination therapy in late-stage development. Meanwhile, the company is adjusting its site strategy and using the recent capital raise to reduce cash burn.

France's decision to broaden reimbursement eligibility marks a key step for the therapy's availability. Patients with two hard-to-treat cancers now have improved access to the treatment under the national healthcare system.

The expanded reimbursement in France comes as Agenus strengthens its financial position through the Zydus partnership. With the Phase 3 trial set for 2026, the company aims to advance its therapy while managing costs. The deal and regulatory progress provide a clearer path for wider patient access in the future.